St. Jude Medical Announces European CE Mark Approval and First Implant of Industry’s First Quadripolar Pacing System

St. Jude Medical, Inc. (NYSE: STJ) today announced it has received European CE Mark approval for the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds). The quadripolar system offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure. It integrates multiple pacing options and features that enable physicians to better manage common pacing complications without having to surgically reposition the lead.

"Managing heart failure patients is often challenging and typically involves ongoing medical management,” said Dr. Klaus Gutleben, consultant cardiologist at the Heart and Diabetes Center North Rhine-Westphalia in Bad Oeynhausen, Germany. "This new quadripolar pacing system provides more options for managing the needs of my patients with heart failure and reduces the patient’s risk of needing multiple surgical procedures, which should lead to more efficient patient care.”

The quadripolar system, with the Quartet™ left ventricular pacing lead, features four pacing electrodes on the left ventricular lead – enabling up to 10 pacing configurations. Multiple pacing configurations provide physicians with more options to pace around scar tissue in the heart and avoid common pacing complications without the need to surgically reposition the lead.

Common pacing complications that can occur in patients implanted with a CRT system include high pacing thresholds and unintentional phrenic nerve or diaphragmatic stimulation. Patients with high pacing thresholds require significantly higher energy to pace the heart; this may reduce the device’s battery life or cause pacing to fail. Phrenic nerve and diaphragmatic stimulation occur when the electrical output from a device inadvertently activates the diaphragm muscle (either directly or via the phrenic nerve), causing hiccups upon each pacing stimulus. Both high pacing thresholds and phrenic nerve or diaphragmatic stimulation are often due to the location of the pacing lead electrode.

"The new features offered in this quadripolar system allow me to mitigate potential complications that would otherwise require an invasive procedure to re-place or reposition the left ventricular lead,” said Dr. Johannes Sperzel of the Kerckhoff Klinik in Bad Nauheim, Germany. "Moreover, the lead maintains excellent handling characteristics, as the additional electrodes do not impact my ability to place the lead in the targeted vein.”

In addition to multiple pacing options, the Quartet pacing lead features other St. Jude Medical technologies such as Optim™ insulation – a material that combines the biostability and flexibility of high-performance silicone rubber with the strength, tear resistance and abrasion resistance of polyurethane, to provide increased durability, flexibility and improved handling characteristics – and the "S-curve” design of the QuickFlex™ lead family, which increases stability.

"CRT has been demonstrated as an important treatment in reducing symptoms and slowing the progression of heart failure. This new system gives physicians more control over patient therapy by providing the flexibility to non-invasively adjust the pacing location or configuration,” said Eric S. Fain, M.D., president of the St. Jude Medical Cardiac Rhythm Management Division. "This approval of the industry’s first quadripolar pacing system is demonstrative of St. Jude Medical’s commitment to providing physicians with novel technology that addresses clinical needs.”

Cardiac resynchronization therapy, which can be delivered in an implantable cardioverter defibrillator (ICD) or a pacemaker, resynchronizes the beating of the heart's lower chambers (ventricles), which often beat out of sync in heart failure patients. Studies have shown that CRT can improve the quality of life for many patients with heart failure, a progressive condition in which the heart weakens and loses its ability to pump an adequate supply of blood. Approximately 23 million people worldwide are afflicted with congestive heart failure (CHF), and 2 million new cases of CHF are diagnosed each year worldwide.

The quadripolar CRT-D and Quartet pacing lead will be distributed via a limited launched in Europe, and will be used in the investigational devices exemption (IDE) trial for U.S. Food and Drug Administration (FDA) approval of the commercialized device, which will be called the Promote Quadra™ CRT-D.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 14,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended April 4, 2009 and July 4, 2009. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.